Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 9/2023

14.09.2023 | Onkologische Immuntherapie | Schwerpunkt

Schwerpunkt "Zukunft der Immuncheckpointinhibition"

Aktivierung von Immunzellrezeptoren statt Checkpointblockade

verfasst von: Prof. Dr. Tobias Bald, Dr. Nicole Glodde

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Auszug

Die Hemmung von Immuncheckpoints ist eine onkologische Erfolgsgeschichte. Allerdings sprechen längst nicht alle Behandelten auf diese Form der Immuntherapie an, erleiden schwere Nebenwirkungen oder erfahren im Behandlungsverlauf Wirksamkeitseinbußen infolge von Resistenzen. All das macht die Entwicklung weiterer Therapieansätze erforderlich. Zu solchen neuen Ansätzen, die derzeit erprobt werden, zählt auch die Stimulation von aktivierenden Immunzellrezeptoren. Was sich dahinter genau verbirgt, welche Herausforderungen es dabei gibt und wo das Feld gegenwärtig steht, beleuchten wir in diesem Übersichtsbeitrag. …
Literatur
1.
Zurück zum Zitat Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64 Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64
2.
Zurück zum Zitat Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-92 Cho BC et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(6):781-92
3.
Zurück zum Zitat Curigliano G et al. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3620-9 Curigliano G et al. Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. Clin Cancer Res. 2021;27(13):3620-9
4.
Zurück zum Zitat Landsberg J et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412-6 Landsberg J et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412-6
5.
Zurück zum Zitat Glodde N et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789-802.e9 Glodde N et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789-802.e9
6.
Zurück zum Zitat Effern M et al. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity. 2020;53(3):564-580.e9 Effern M et al. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity. 2020;53(3):564-580.e9
7.
Zurück zum Zitat Klümper N et al. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. Clin Transl Immunology. 2021;10(12):e1358 Klümper N et al. C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma. Clin Transl Immunology. 2021;10(12):e1358
8.
Zurück zum Zitat Hahn AW et al. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681-92 Hahn AW et al. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9(8):681-92
9.
Zurück zum Zitat Mayes PA et al. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(7):509-27 Mayes PA et al. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(7):509-27
10.
Zurück zum Zitat Smith-Garvin JE et al. T Cell Activation. Annu Rev Immunol. 2009;27(1):591-619 Smith-Garvin JE et al. T Cell Activation. Annu Rev Immunol. 2009;27(1):591-619
11.
Zurück zum Zitat Schwartz JCD et al. Structural mechanisms of costimulation. Nat Immunol. 2002;3(5):427-34 Schwartz JCD et al. Structural mechanisms of costimulation. Nat Immunol. 2002;3(5):427-34
12.
Zurück zum Zitat Zhang Q, Vignali DAA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016;44(5):1034-51 Zhang Q, Vignali DAA. Co-stimulatory and Co-inhibitory Pathways in Autoimmunity. Immunity. 2016;44(5):1034-51
13.
Zurück zum Zitat Suntharalingam G et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med. 2006;355(10):1018-28 Suntharalingam G et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med. 2006;355(10):1018-28
14.
Zurück zum Zitat Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12(5):317-8 Hünig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12(5):317-8
15.
Zurück zum Zitat French RR et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5(5):548-53 French RR et al. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5(5):548-53
16.
Zurück zum Zitat Barlesi F et al. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. J Immunother Cancer. 2020; https://doi.org/kmw5 Barlesi F et al. 291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors. J Immunother Cancer. 2020; https://​doi.​org/​kmw5
17.
Zurück zum Zitat Padrón LJ et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167-77 Padrón LJ et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 2022;28(6):1167-77
18.
Zurück zum Zitat Djureinovic D et al. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021;13(6):1302 Djureinovic D et al. Agonistic CD40 Antibodies in Cancer Treatment. Cancers (Basel). 2021;13(6):1302
19.
Zurück zum Zitat Kjaergaard J et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514-21 Kjaergaard J et al. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res. 2000;60(19):5514-21
20.
Zurück zum Zitat Postel-Vinay S et al. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023;11(3):e005301 Postel-Vinay S et al. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023;11(3):e005301
21.
Zurück zum Zitat Yadav R, Redmond WL. Current Clinical Trial Landscape of OX40 Agonists. Curr Oncol Rep. 2022;24(7):951-60 Yadav R, Redmond WL. Current Clinical Trial Landscape of OX40 Agonists. Curr Oncol Rep. 2022;24(7):951-60
22.
Zurück zum Zitat Melero I et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682-5 Melero I et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997;3(6):682-5
23.
Zurück zum Zitat Chu DT et al. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol Sci. 2019;20(8):1822 Chu DT et al. An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer. Int J Mol Sci. 2019;20(8):1822
24.
Zurück zum Zitat Segal NH et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017;23(8):1929-36 Segal NH et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017;23(8):1929-36
25.
Zurück zum Zitat Claus C et al. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs. 2023;15(1):2167189 Claus C et al. The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy. MAbs. 2023;15(1):2167189
26.
Zurück zum Zitat Chester C et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49-57 Chester C et al. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2018;131(1):49-57
27.
Zurück zum Zitat Labrijn AF et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585-608 Labrijn AF et al. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585-608
28.
Zurück zum Zitat Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65 Budde LE et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-65
29.
Zurück zum Zitat Kantarjian H et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-47 Kantarjian H et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-47
Metadaten
Titel
Schwerpunkt "Zukunft der Immuncheckpointinhibition"
Aktivierung von Immunzellrezeptoren statt Checkpointblockade
verfasst von
Prof. Dr. Tobias Bald
Dr. Nicole Glodde
Publikationsdatum
14.09.2023
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 9/2023
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-023-0035-6

Weitere Artikel der Ausgabe 9/2023

InFo Hämatologie + Onkologie 9/2023 Zur Ausgabe

Neues aus der Forschung

Bessere GvHD-Prophylaxe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.